###begin article-title 0
Circulating Vitamin D and Risk of Epithelial Ovarian Cancer
###end article-title 0
###begin p 1
Recommended by Boffetta Paolo
###end p 1
###begin p 2
###xml 710 713 710 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 97 102 <span type="species:ncbi:9606">Women</span>
We conducted a nested case-control study within two prospective cohorts, the New York University Women's Health Study and the Northern Sweden Health and Disease Study, to examine the association between prediagnostic circulating levels of 25-hydroxy vitamin D (25(OH)D) and the risk of subsequent invasive epithelial ovarian cancer (EOC). The 25(OH)D levels were measured in serum or plasma from 170 incident cases of EOC and 373 matched controls. Overall, circulating 25(OH)D levels were not associated with the risk of EOC in combined cohort analysis: adjusted OR for the top tertile versus the reference tertile, 1.09 (95% CI, 0.59-2.01). In addition, there was no evidence of an interaction effect between VDR SNP genotype or haplotype and circulating 25(OH)D levels in relation to ovarian cancer risk, although more complex gene-environment interactions may exist.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
There is considerable interest in understanding the role of vitamin D in cancer in general and in ovarian cancer in particular. Experimental studies have shown that vitamin D administration reduces proliferation and promotes apoptosis in ovarian cancer cell lines and animal models [1-6]. Ovarian cancer incidence and mortality rates are higher in northern latitudes, where sun exposure, which is required for the initiation of vitamin D synthesis in the skin, is lower [7-10]. An inverse association between dietary vitamin D intake and risk of ovarian cancer has been reported in one epidemiologic study [11], although others have not supported this finding [12-16]. Studies of the effect of dietary vitamin D intake are limited because estimation of dietary vitamin D intake does not capture cutaneous production of vitamin D. Thus, circulating vitamin D, which reflects both cutaneous production and dietary/supplement intake [17-20], is considered the best indicator of overall vitamin D status.
###end p 4
###begin p 5
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 330 331 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
1,25(OH)2D is the biologically active vitamin D metabolite. However, its concentration is about 1000 times lower than that of 25(OH)D in circulation, due to its shorter half-life and local production in target tissues, such as the ovaries [21, 22]. Thus, 25(OH)D is thought to better reflect overall vitamin D status than 1,25(OH)2 D [23, 24]. 
###end p 5
###begin p 6
###xml 258 259 258 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
To date, only one epidemiologic study has examined the relationship between prediagnostic levels of vitamin D and risk of ovarian cancer. Tworoger et al. did not find an association of ovarian cancer risk with the 25(OH)D or 1,25-dihydroxyvitamin D (1,25(OH)2D) plasma levels [25].
###end p 6
###begin p 7
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm1</italic>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa1</italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq1</italic>
###xml 306 310 306 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fok1</italic>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fok1</italic>
###xml 708 711 708 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 668 673 <span type="species:ncbi:9606">women</span>
Polymorphisms in the VDR gene may influence the ability of 1,25(OH)2D to activate vitamin D target genes, including those involved in growth regulation and apoptosis. In a previous manuscript, we reported an overall null association between four common polymorphisms in the VDR gene (Bsm1, Apa1, Taq1, and Fok1) and risk of ovarian cancer [26], although a retrospective multiethnic study of 313 cases and 574 controls [27] and a large pooled analysis including 1473 cases and 2006 controls from four studies (one retrospective case-control study and three case-control studies nested in prospective cohorts) [28] found an association with the Fok1 SNP among Caucasian women. Mixed results for this and other VDR SNPs may be due to chance findings or limited power to detect associations [27]. It is also possible that genetic variants influence ovarian cancer risk differently, depending on an individual's vitamin D status. 
###end p 7
###begin p 8
###xml 213 216 213 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
The objective of the present study was to examine the relationship between circulating levels of 25(OH)D and risk of invasive epithelial ovarian cancer and to assess the combined effect of circulating 25(OH)D and VDR polymorphisms on ovarian cancer risk.
###end p 8
###begin title 9
2. Methods
###end title 9
###begin title 10
2.1. Study Population
###end title 10
###begin p 11
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 116 121 <span type="species:ncbi:9606">Women</span>
###xml 249 254 <span type="species:ncbi:9606">women</span>
###xml 374 379 <span type="species:ncbi:9606">women</span>
###xml 1349 1361 <span type="species:ncbi:9606">Participants</span>
Descriptions of the University of Umea Northern Sweden Health and Disease Study (NSHDS) and the New York University Women's Health Study (NYUWHS) have been provided previously [29-31]. Briefly, since 1985 the NSHDS has enrolled approximately 53 756 women aged 30-65 through local health promotion intervention programs in Northern Sweden. The NYUWHS enrolled 14 274 healthy women aged 34-65 years at a breast cancer screening center in New York City between 1985 and 1991. Each study cohort collected information about medical history, reproductive history, family history of cancer, medications, smoking history, and diet during enrollment and/or followup. Blood collected at enrollment and any subsequent visits was processed according to standardized procedures within each cohort. In the NSHDS cohort, blood was collected, centrifuged, and plasma aliquots were frozen at -80degreesC and transferred within 1 week to a -80degreesC central storage facility (the Northern Sweden Medical Research Biobank). In the NYUWHS cohort, blood was drawn, collection tubes were kept covered at room temperature (21-25degreesC) for 15 minutes, then at 4degreesC for 60 minutes to allow clot retraction, and then centrifuged for 25 minutes. After centrifugation, serum samples were divided into aliquots and immediately stored at -80degreesC at the local site. Participants who reported being pregnant or using exogenous hormones within 6 months of enrollment were not eligible for the NYUWHS cohort or for case-control selection from NSHDS.
###end p 11
###begin title 12
2.2. Case Ascertainment
###end title 12
###begin p 13
###xml 984 987 984 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
In the NSHDS, cohort linkages to regional and national cancer registries and to all-cause mortality registries were used to capture cases of incident invasive epithelial ovarian cancer. In the NYUWHS cohort, case ascertainment was achieved through self report on followup questionnaires and through linkages with state tumor registries in New York, New Jersey, and Florida. Medical records were obtained to verify reported events. As of November 1, 2005, a total of 192 invasive ovarian cancer cases (107 from the NSHDS and 85 from the NYUWHS) had been identified. Twenty-two nonepithelial ovarian cancer cases (8 from the NSHDS and 14 from the NYUWHS) were excluded from this study because they did not meet the criteria of being invasive epithelial ovarian cancer. For the current study, there were a total of 170 invasive EOC cases (71 from NYUWHS and 99 from NSHDS). However, two cases from the NSHDS cohort had only DNA available for analysis, and were only included in the main VDR genotyping analysis [26].
###end p 13
###begin title 14
2.3. Selection of Controls
###end title 14
###begin p 15
For each case, two controls were randomly selected from cohort members who were alive and free of cancer at the time of diagnosis of the case. Controls were also matched to the case on cohort (NYUWHS or NSHDS), age at entry (+/-6 months) and date of blood donation (+/-15 days). Seventeen cases from the NYUWHS cohort had only one eligible matched control because 10 controls had a complete bilateral oophorectomy before the diagnosis date of the case and seven cases could not be sufficiently closely matched to a second control on date of blood donation (strict matching is required to control for seasonal effects of vitamin D). Of the potential 323 eligible controls in total (198 from the NSHDS, 125 from the NYUWHS), seven were excluded from the NSDHS because either the control or matching case did not have plasma available.
###end p 15
###begin p 16
The institutional review boards of New York University School of Medicine and the Regional Ethical Committee of the University of Umea, Sweden, and the Swedish Data Inspection Board reviewed and approved this study.
###end p 16
###begin title 17
2.4. Laboratory Methods
###end title 17
###begin p 18
###xml 241 246 <span type="species:ncbi:9940">sheep</span>
Serum 25(OH)D was measured at the University of Umea using a gamma-B 25-hydroxy vitamin D radioimmunoassay (Immunodiagnostic Systems (IDS), Inc.). Acetonitrile extraction of 25(OH)D was followed by incubation with radioionidated tracers and sheep antibodies to 25(OH)D. Antibody-bound tracer is inversely proportional to the concentration of 25(OH)D. Samples from each cohort and case-control set were assayed together in the same laboratory batch. Quality controls and study samples were distributed randomly throughout the batches and the laboratory personnel were blinded to the samples' case-control status. The intra- and interbatch coefficients of variation were 17.7% and 24.6% for NSHDS, respectively. For NYUWHS, the intra- and interbatch coefficients of variation were 16.6% and 16.2%, respectively. 
###end p 18
###begin p 19
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
Genotyping was performed at New York University School of Medicine. Methods, quality control procedures, and genotyping success rates have been reported previously [26].
###end p 19
###begin title 20
2.5. Statistical Analysis
###end title 20
###begin p 21
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 198 199 198 199 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</bold>
###xml 1847 1849 1847 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 3006 3009 3004 3007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 212 224 <span type="species:ncbi:9606">participants</span>
###xml 369 381 <span type="species:ncbi:9606">participants</span>
25(OH)D values were log 2 transformed to reduce departures from the normal distribution (the log 2 transformation is useful for estimating odds ratios associated with a doubling in vitamin D levels). Two control participants in the NYUWHS cohort with outlying values for 25(OH)D (>150 nmol/L) were set to missing. Odds ratios from analyses including or excluding these participants did not differ appreciably. Linear regression and ANOVA were used to test whether 25(OH)D levels differed according to baseline characteristics. Conditional logistic regression, which allows for the matched design, was used to evaluate the association between serum concentration of 25(OH)D and risk of EOC. Because cases were individually matched to controls for laboratory batch and date of sampling (i.e., season), these variables were controlled for by design when 25(OH)D was modeled as a continuous variable. To create meaningful tertiles of 25(OH)D for categorical analysis, however, the 25(OH)D values needed to be laboratory batch and season, to prevent individuals from being arbitrarily included in a tertile simply on the basis of their season of blood draw or inclusion in a particular batch. The adjustment for laboratory batch was done by first regressing the log-transformed 25(OH)D values on season, age, and BMI (the three variables that were associated with 25(OH)D) and computing the residuals within each cohort. We then computed the mean residual for each laboratory batch and subtracted the appropriate batch mean from each individual's log-transformed vitamin D value to center each batch at the grand mean for each cohort. We then adjusted for seasonal effects by performing a nonparametric local regression (Proc Loess, SAS) of 25(OH)D values on day of the year of blood donation and used the residuals to create cohort-specific tertiles [32]. Potential confounders, specifically reproductive history (parity, number of full-term pregnancies, and age at first full-term pregnancy), age at menarche, menopausal status at enrollment, history of oral contraceptive use at baseline, body mass index at enrollment, and smoking status at baseline (never, current, former) were considered in the logistic regression models. However, the only variables significantly different between cases and controls were parity and oral contraceptive use (both categorized as ever/never). Therefore, multivariate models included only these two variables (age and date of blood donation which were controlled for by the matched design and use of the conditional logistic regression model). An indicator variable for sample type (serum versus plasma) also was examined as a potential interaction term. We also conducted analyses excluding individuals diagnosed within five years of blood donation, and evaluated the vitamin D-ovarian cancer relationship within histological subtypes, and by stage (I-II versus III-IV), grade, BMI (dichotomous variable < 25 versus >/=25), oral contraceptive use (ever versus never), and VDR SNP genotype (assuming a codominant model). Haplotypes were estimated from genotype data using PHASE version 2.1.1 () and odds ratios for the interaction between having zero, one, or two copies of the haplotype and 25(OH)D levels were determined using conditional logistic regression. We used SAS software (version 9.1, SAS institute, Cary, NC) for all statistical analyses.
###end p 21
###begin title 22
3. Results
###end title 22
###begin p 23
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 151 158 151 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 504 505 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 573 574 573 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 816 817 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 889 890 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 961 962 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1015 1016 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1081 1082 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1178 1181 1178 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1219 1221 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 33 45 <span type="species:ncbi:9606">participants</span>
###xml 230 242 <span type="species:ncbi:9606">participants</span>
The characteristics of the study participants from each cohort at baseline have been described previously [26]. An abbreviated description is shown in Table 1. The median age at enrollment was 52 and 55 years for NSHDS and NYUWHS participants, respectively. NSHDS cases had a median of 4.6 years between blood donation and diagnosis and NYUWHS cases were diagnosed an average of 7.0 years after blood donation. NSHDS cases were less likely than NSHDS controls to have ever been pregnant (78% versus 89%, P = .01) and to have ever taken oral contraceptives (33% versus 45%, P = .03). NYUWHS cases and controls were not significantly different with regard to their baseline characteristics. Regarding differences between cohorts, NYUWHS controls were more likely than NSHDS controls to be nulliparous (31% versus 11%, P < .0001), more likely to be premenopausal at baseline (42% versus 28%, P = .01), less likely to have used oral contraceptives (32% versus 45%, P = .03), more likely to have smoked (61% versus 43%, P = .01), and had higher 25(OH)D levels (45.8 versus 39.4 nmol/L, P = .04). Cases and controls did not differ with regard to genotype frequency at any of the four VDR SNP sites for either of the cohorts [26].
###end p 23
###begin p 24
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2 </xref>
###xml 683 686 683 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm1</italic>
###xml 729 730 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 742 746 742 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq1</italic>
###xml 748 749 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 763 770 763 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 854 858 854 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm1</italic>
###xml 862 866 862 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa1</italic>
###xml 874 878 874 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq1</italic>
###xml 1008 1015 1008 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 141 146 <span type="species:ncbi:9606">women</span>
###xml 183 188 <span type="species:ncbi:9606">women</span>
###xml 236 241 <span type="species:ncbi:9606">women</span>
###xml 790 795 <span type="species:ncbi:9606">women</span>
Table 2 shows 25(OH)D by characteristics of controls for the NSHDS and NYUWHS cohorts. In both cohorts, median 25(OH)D levels were higher in women who were older at enrollment and in women who had lower BMI, and were somewhat higher in women who were ever parous and had used oral contraceptives. However, the two cohorts differed with regard to smoking status: in the NYUWHS, current smokers had higher median 25(OH)D levels (50 nmol/L in current versus ~45 nmol/L in former and never smokers), while smoking in the NSHDS showed a somewhat opposite relationship with 25(OH)D (~38 nmol/L in current and former versus 40 nmol/L in never smokers). 25(OH)D was only modestly related to VDR genotype in the NSHDS cohort at the Bsm1 (P = .16) and Taq1 (P = .19) loci (Table 3). In both cohorts, women with two copies of the baT haplotype (associated with the Bsm1 G, Apa1 G, and Taq1 T allele combination) had higher levels of circulating 25(OH)D, although the tests for trend were not statistically significant (Table 3).
###end p 24
###begin p 25
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 307 308 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 410 417 410 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 706 707 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 743 746 741 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
We did not observe an overall association between vitamin D and ovarian cancer when 25(OH)D was modeled on the continuous (multivariate adjusted OR for a doubling in vitamin D levels = 1.1, 95% CI: 0.7-1.7 ) or categorical scale (Table 4). There was some evidence of interaction between 25(OH)D and cohort (P = .07), though cohort-specific odds ratios do not support an association with risk in either cohort (Table 4). The lack of association between vitamin D and ovarian cancer remained after controlling for parity and oral contraceptive use. We did not observe any significant differences in the relationship between 25(OH)D and ovarian cancer by season of blood collection, BMI (<25 versus >/=25 kg/m2), menopausal status at enrollment, VDR SNP genotype or haplotype, tumor stage (I-II versus III-IV), grade, or histological subtype (serous versus mucinous, clear cell, and endometriod) (data not shown). Odds ratios for 25(OH)D and risk of ovarian cancer did not change appreciably in analyses restricted to 74 matched sets in which cases were diagnosed five or more years after blood donation (OR for the highest versus lowest tertile = 0.9, 95% CI: 0.46-1.72).
###end p 25
###begin title 26
4. Discussion
###end title 26
###begin p 27
###xml 336 339 336 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
In the current study, we did not observe an association between circulating levels of 25(OH)D and risk of epithelial ovarian cancer. The lack of an association remained after controlling for potential confounders, excluding cases diagnosed within 5 years of blood donation, and considering subgroups defined by genetic variation in the VDR, tumor characteristics (i.e., stage, grade, and histological subtype), menopausal status, and BMI.
###end p 27
###begin p 28
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 753 756 753 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 870 871 868 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 873 875 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 844 849 <span type="species:ncbi:9606">women</span>
Initial support for a protective role for vitamin D was provided by ecological studies showing an inverse association between UV-B exposure and ovarian cancer incidence or mortality rates [7-10]. However, research conducted with this type of study design cannot elucidate the temporal association between exposure and disease. Case-control and cohort studies of dietary vitamin D intake and risk of ovarian cancer have been inconsistent [11-16]. The results of our study are in agreement with the overall results of Tworoger et al. [25], the only other prospective study of ovarian cancer to report on circulating 25(OH)D to date. Our study similarly found that the lack of association between serum 25(OH)D and risk of ovarian cancer did not differ by VDR genotype [28]. However, Tworoger et al. found an inverse association for 25(OH)D among women with BMI >/= 25 kg/m2 [25], which was not observed in the current study.
###end p 28
###begin p 29
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 970 972 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1002 1006 1002 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm1</italic>
###xml 1010 1014 1010 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa1</italic>
###xml 1022 1026 1022 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq1</italic>
###xml 1047 1050 1047 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1142 1145 1142 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1251 1255 1251 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm1</italic>
###xml 1404 1405 1404 1405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1428 1430 1428 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1515 1516 1515 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1616 1618 1616 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 1691 1694 1691 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 1722 1724 1722 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1777 1781 1777 1781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm1</italic>
###xml 1785 1789 1785 1789 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa1</italic>
###xml 1797 1801 1797 1801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq1</italic>
###xml 1868 1869 1868 1869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1884 1886 1884 1886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1928 1932 1928 1932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bsm1</italic>
###xml 1936 1940 1936 1940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apa1</italic>
###xml 1948 1952 1948 1952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq1</italic>
###xml 162 169 <span type="species:ncbi:9606">persons</span>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 634 639 <span type="species:ncbi:9606">women</span>
###xml 1423 1426 <span type="species:ncbi:9606">men</span>
###xml 1652 1657 <span type="species:ncbi:9606">women</span>
Consistent with previous studies [33-37], higher BMI was associated with lower circulating 25(OH)D in both cohorts. Vitamin D is fat-soluble and studies in obese persons and mice have shown increased storage and decreased bioavailability of vitamin D in fat cells [38, 39]. We also observed that parity was associated with higher 25(OH)D; which is in agreement with a similar observation in the PLCO Cancer Screening Trial [37]. Contrary to some previous reports [37, 40, 41], we observed a positive relationship between age and 25(OH)D, which showed increased levels of vitamin D in the 50-60 year age group as compared with younger women. This may be due to an increased intake of calcium and vitamin D-rich foods and supplements around the time of menopause in an effort to prevent or treat osteoporosis. Oral contraceptive use was associated with higher median 25(OH)D levels in our study; previous studies have found a similar relationship in current OC users [17, 42, 43]. We also found that the Bsm1 G, Apa1 G, and Taq1 T haplotype, in the VDR gene was modestly associated with higher 25(OH)D. Publications on the relationship between VDR genotype and levels of 25(OH)D have been fairly inconsistent. In the Physicians Health Study Cohort, the Bsm1 genotype was not related to total 25(OH)D levels, although the BB genotype was associated with higher index of free 25(OH)D and with higher 1,25(OH)2D levels in older men [44]. The BB genotype was also associated with higher 25(OH)D in a small Finnish study (n = 93) that collected all blood samples in the winter when skin synthesis of vitamin D is very low [45]. However, a large study of 2845 women found no association between any VDR SNPs genotype and 25(OH)D [46]. Individuals with two copies of the bAT haplotype (Bsm1 G, Apa1 T, and Taq1 T) had lower levels of 25(OH)D than individuals with 0 or 1 copy (P-trend = .09) [46]. Individuals without any copies of baT (Bsm1 G, Apa1 G, and Taq1 T) in the current study (which would include all individuals with two copies of the bAT haplotype) had lower 25(OH)D levels, thus providing indirect support for the previous finding. 
###end p 29
###begin p 30
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 1464 1466 1464 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 76 87 <span type="species:ncbi:9606">participant</span>
###xml 181 193 <span type="species:ncbi:9606">participants</span>
###xml 1473 1478 <span type="species:ncbi:9606">women</span>
###xml 1565 1570 <span type="species:ncbi:9606">women</span>
This study limitations include the use of only one sample to determine each participant's 25(OH)D status. However, in a preliminary reproducibility study of 25(OH)D among 16 NYUWHS participants with at least 3 annual visits, the intraclass correlation coefficient was quite high (0.71), suggesting stability of this metabolite from visit to visit, which has been observed by others [47, 48]. The relatively high coefficient of variation for the 25(OH)D assay adds random error to the measurements and may have attenuated the association. Potential residual confounding and relatively small sample size are additional limitations. Although we had sufficient sample size to detect small differences between cases and controls (a priori, we had 80% power to detect a mean difference of 6 nmol/L between cases and controls), we had limited ability to explore interactions. Previous studies have demonstrated that vitamin D deficiency is more common in Europe than the United States, and that in the United States, the latitude of residence is inversely associated with vitamin D (reviewed in [49]). We anticipated that the ranges of 25(OH)D values in the New York and Northern Sweden populations would be lower than those reported from lower latitudes [50, 51]. In the highest tertile, the median value for 25(OH)D was 68.9 nmol/L for NYUWHS and 51.6 nmol/L for NSHDS; somewhat lower than the 75 nmol/L, that is, considered to be optimal for multiple health outcomes [52]. Few women in our study had levels above 75 nmol/L, thus we cannot rule out the possibility that women with very high 25(OH)D levels may have a reduced risk of ovarian cancer. Strengths of the study include the use of samples collected before diagnosis, limiting the potential for existing disease to influence vitamin D levels, the use of circulating 25(OH)D as a composite measure of vitamin D overall status, careful consideration of seasonal effects, and the use of a nested case-control design, which helps ensure that the controls are comparable to the cases. 
###end p 30
###begin p 31
In conclusion, our findings do not provide support for the hypothesis that circulating vitamin D levels are associated with risk of invasive epithelial ovarian cancer later in life. Larger studies are needed to evaluate gene-environment interactions and potential subgroups which may benefit from vitamin D chemoprevention.
###end p 31
###begin title 32
Acknowledgments
###end title 32
###begin p 33
###xml 22 34 <span type="species:ncbi:9606">participants</span>
###xml 210 214 <span type="species:ncbi:9689">Lion</span>
###xml 425 430 <span type="species:ncbi:9606">Women</span>
The authors thank the participants of the NYUWHS and the NSHDS, whose participation made this project possible. They would like to thank Yelena Afanasyeva for database management. They would also like to thank Lion's Cancer Foundation at Umea University, Sweden, for supporting this project. This work is primarily supported by research grant R03CA096428 from the National Institutes of Health (NIH). The New York University Women's Health Study is supported by research grants R01CA034588, R01CA098661, center grant P30CA016087 from the National Cancer Institute, and the center grant ES000260 from the National Institute of Environmental Health Sciences. The Northern Sweden Health and Disease Study is sponsored by the Swedish Cancer Society. The first two authors contributed equally to this work.
###end p 33
###begin article-title 34
The ovary: a target organ for 1,25-dihydroxyvitamin D3
###end article-title 34
###begin article-title 35
Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone
###end article-title 35
###begin article-title 36
G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer
###end article-title 36
###begin article-title 37
Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase
###end article-title 37
###begin article-title 38
p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase
###end article-title 38
###begin article-title 39
###xml 51 60 <span type="species:ncbi:10090">nude mice</span>
Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089
###end article-title 39
###begin article-title 40
###xml 62 67 <span type="species:ncbi:9606">women</span>
Sunlight, vitamin D, and ovarian cancer mortality rates in US women
###end article-title 40
###begin article-title 41
An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation
###end article-title 41
###begin article-title 42
Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study
###end article-title 42
###begin article-title 43
Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer
###end article-title 43
###begin article-title 44
Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico
###end article-title 44
###begin article-title 45
Prospective study of diet and ovarian cancer
###end article-title 45
###begin article-title 46
Micronutrients and ovarian cancer: a case-control study in Italy
###end article-title 46
###begin article-title 47
Association of dairy products, lactose, and calcium with the risk of ovarian cancer
###end article-title 47
###begin article-title 48
Relationship between calcium, lactose, vitamin D, and dairy products and ovarian cancer
###end article-title 48
###begin article-title 49
Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies
###end article-title 49
###begin article-title 50
###xml 68 73 <span type="species:ncbi:9606">women</span>
Parameters related to 25-OH-D levels in a population-based study of women
###end article-title 50
###begin article-title 51
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol
###end article-title 51
###begin article-title 52
###xml 108 113 <span type="species:ncbi:9606">women</span>
Associations of diet, supplement use, and ultraviolet B radiation exposure with vitamin D status in Swedish women during winter
###end article-title 52
###begin article-title 53
Association of vitamin D-related information from a telephone interview with 25-hydroxyvitamin D
###end article-title 53
###begin article-title 54
Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease
###end article-title 54
###begin article-title 55
Blood biomarkers of vitamin D status
###end article-title 55
###begin article-title 56
Vitamin D status: measurement, interpretation, and clinical application
###end article-title 56
###begin article-title 57
The vitamin D questions: how much do you need and how should you get it?
###end article-title 57
###begin article-title 58
Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer
###end article-title 58
###begin article-title 59
Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer
###end article-title 59
###begin article-title 60
Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk
###end article-title 60
###begin article-title 61
Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies
###end article-title 61
###begin article-title 62
Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort-evaluation of risk factors and their interactions
###end article-title 62
###begin article-title 63
Endogenous hormones and breast cancer: a prospective cohort study
###end article-title 63
###begin article-title 64
###xml 80 85 <span type="species:ncbi:9606">women</span>
A prospective study of endogenous estrogens and breast cancer in postmenopausal women
###end article-title 64
###begin article-title 65
Using lowess to remove systematic trends over time in predictor variables prior to logistic regression with quantile categories
###end article-title 65
###begin article-title 66
###xml 59 64 <span type="species:ncbi:9606">women</span>
Body fat content and 25-hydroxyvitamin D levels in healthy women
###end article-title 66
###begin article-title 67
Relationship between 25-(OH) D3, the IGF-I system, leptin, anthropometric and body composition variables in a healthy, randomly selected population
###end article-title 67
###begin article-title 68
###xml 42 47 <span type="species:ncbi:9606">women</span>
Determinants of vitamin D status in older women living in a subtropical climate
###end article-title 68
###begin article-title 69
###xml 108 111 <span type="species:ncbi:9606">men</span>
###xml 116 121 <span type="species:ncbi:9606">women</span>
Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women
###end article-title 69
###begin article-title 70
Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
###end article-title 70
###begin article-title 71
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat adipose tissue rapidly accumulates and slowly releases an orally-administered high vitamin D dose
###end article-title 71
###begin article-title 72
Vitamin D(3) in fat tissue
###end article-title 72
###begin article-title 73
Vitamin D status and the risk of lung cancer: a cohort study in Finland
###end article-title 73
###begin article-title 74
###xml 62 67 <span type="species:ncbi:9606">women</span>
Plasma vitamin D metabolites and risk of colorectal cancer in women
###end article-title 74
###begin article-title 75
The association of oral contraceptive use with plasma 25-hydroxyvitamin D levels
###end article-title 75
###begin article-title 76
###xml 79 84 <span type="species:ncbi:9606">women</span>
Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third national health and nutrition examination survey, 1988-1994
###end article-title 76
###begin article-title 77
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians
###end article-title 77
###begin article-title 78
###xml 86 91 <span type="species:ncbi:9606">women</span>
Vitamin D receptor gene BsmI-polymorphism in Finnish premenopausal and postmenopausal women: its association with bone mineral density, markers of bone turnover, and intestinal calcium absorption, with adjustment for lifestyle factors
###end article-title 78
###begin article-title 79
###xml 103 106 103 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDR</italic>
###xml 131 136 <span type="species:ncbi:9606">women</span>
Large-scale population-based study shows no evidence of association between common polymorphism of the VDR gene and BMD in British women
###end article-title 79
###begin article-title 80
Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group
###end article-title 80
###begin article-title 81
Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer
###end article-title 81
###begin article-title 82
Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications
###end article-title 82
###begin article-title 83
The role of vitamin D in cancer prevention
###end article-title 83
###begin article-title 84
Vitamin D requirement and setting recommendation levels-current Nordic view
###end article-title 84
###begin article-title 85
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes
###end article-title 85
###begin p 86
Characteristics of invasive epithelial ovarian cancer cases and matched controls, NYUWHS and NSHDS cohorts.
###end p 86
###begin p 87
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
*Differs significantly between NYUWHS and NSHDS cases at P = .0001. 
###end p 87
###begin p 88
###xml 0 6 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 54 55 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
daggerNYUWHS and NSHDS controls differ significantly (P < .05) with regard to age at menarche, menopausal status, parity, ever use of oral contraceptives, smoking status, and 25(OH)D. 
###end p 88
###begin p 89
###xml 0 13 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 77 78 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 119 120 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
double daggerCase-control differences significant only for NSHDS for parity (P = .01) and for oral contraceptives use (P = .03).
###end p 89
###begin p 90
Circulating 25(OH)D levels by baseline characteristics, NYUWHS and NSHDS controls.
###end p 90
###begin p 91
*All variables had missing data for fewer than 7 controls except for NHSDS: parity (19 missing), oral contraceptives use (28 missing), and smoking (15 missing), and for NYUWHS: oral contraceptives use (33 missing) and smoking (27 missing).
###end p 91
###begin p 92
Circulating 25(OH)D levels by vitamin D receptor Fok1 genotype and Bsm1, Apa1, and Taq1 haplotype, NYUWHS and NSHDS controls.
###end p 92
###begin p 93
Odds ratios for invasive epithelial ovarian cancer by tertile of 25(OH)D.
###end p 93
###begin p 94
*Conditional logistic regression model controlling for matching factors only: cohort, age at entry, and date of blood donation. 
###end p 94
###begin p 95
###xml 0 7 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224; </sup>
###xml 251 252 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 266 267 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 191 203 <span type="species:ncbi:9606">participants</span>
dagger Conditional logistic regression model controlling for matching factors and additionally adjusted for oral contraceptive use (ever/never) and parity (ever/never) after exclusion of the participants with missing data for these variables (NYUWHS: n = 49, NSHDS: n = 49). 
###end p 95

